Humira maker AbbVie to acquire Botox maker Allergan for $63 billion

Botox Maker Allergan Is Sold to AbbVie in $63 Billion Deal

The drugmaker AbbVie said on Tuesday that it planned to buy Allergan, the maker of Botox, for about $63 billion, in one of the biggest mergers in the health ...

AbbVie looks beyond Humira with $63 billion deal for Botox-maker ...

Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion, giving AbbVie control over the lucrative wrinkle ...

AbbVie to buy Botox maker Allergan for $63 billion - CBS News

AbbVie said it will buy Allergan for $63 billion, a move designed to diversify AbbVie's drug lineup before Humira, its blockbuster immune disorder treatment, ...

Maker Of Botox Is Sold To AbbVie In $63 Billion Deal

The drugmaker AbbVie, owner of the top-selling drug Humira, announced on Tuesday, June 25, it will buy Allergan for $63 billion.

Humira maker AbbVie to acquire Botox maker Allergan for $63 billion

Humira maker AbbVie is set to acquire Botox maker Allergan in another move toward consolidation for the pharmaceutical industry.

AbbVie to acquire Allergan for $63 billion - C&EN

Staring down a future without the lucrative arthritis treatment Humira, AbbVie has responded with a deal to acquire Allergan for $63 billion.

AbbVie is nearing a deal to buy Allergan for more than $60 billion

AbbVie looks beyond Humira with a $63 billion deal for Botox-maker Allergan · AbbVie said it would buy Botox-maker Allergan for about $63 billion ...

Abbvie Drops by a Record as Allergan Deal Fails to End Doubts

AbbVie Inc. agreed to pay $63 billion for rival drugmaker Allergan Plc, the latest merger in an industry where some of the biggest companies have been willing ...

AbbVie buying Allergan in $63B deal for its post-Humira future

AbbVie on Tuesday announced it will acquire Allergan in a $63 billion deal, delivering a forceful answer to growing shareholder questions ...

AbbVie Strikes Deal to Acquire Allergan for About $63 Billion - WSJ

Buying Dublin-based Allergan would deliver a dominant position in the $8 billion-plus market for Botox and other beauty drugs, as well as a ...

AbbVie buying Allergan for $63 billion - Crain's Chicago Business

The deal for the Botox maker comes as AbbVie eyes the end of patent protection for Humira, the world's best-selling drug.

AbbVie makes $63-billion bid to buy Botox maker Allergan – San ...

Humira logged $20 billion in sales last year, or about 61% of AbbVie's revenue. That dangerous dependence on one drug pushed AbbVie to make a big move.

AbbVie to buy Botox maker Allergan for $63B - MedCity News

Chicago-based AbbVie said Tuesday it would acquire Ireland-headquartered Allergan for $63 billion, or $78.45 per share, equal to the former's ...

Abbvie to buy Allergan in $63bn deal - Financier Worldwide

Drug manufacturer Abbvie Inc is to acquire Irish rival Allergan Plc for around $63bn in a cash and stock transaction.

AbbVie Buys Botox Maker Allergan in Blockbuster $63 Billion Deal

The specialty drug company AbbVie will spend $63 billion to acquire Allergan, the maker of Botox and other cosmetic treatments.

Allergan stock surges on news that Abbvie will buy Botox maker in a ...

The maker of Botox will be bought by Abbvie in a cash and stock deal valued at about $63 billion, the companies announced Tuesday. The purchase ...

AbbVie To Buy Allergan For $63B - Contract Pharma

AbbVie struck a deal to buy Botox-maker, and the biggest name in medical aesthetics, Allergan, for roughly $63 billion.

Illinois-based drugmaker AbbVie to buy rival - Near West

North Chicago-based drugmaker AbbVie is buying Botox-maker Allergan for $63 billion in cash and stock — a deal designed to reduce AbbVie's reliance on its ...

AbbVie Completes Transformative Acquisition of Allergan - May 8 ...

This diversified on-market portfolio will drive the existing AbbVie growth platform (ex-Humira) to approximately $30 billion in revenues in full ...

AbbVie makes $63B bid for Botox maker Allergan - FOX Chattanooga

Facing competition for the world's top-selling drug, AbbVie will spend about $63 billion to buy Botox maker Allergan as it attempts to spur future growth.